
A new UBCO study finds people are using small doses of psychedelics not for recreational purposes, but to combat anxiety and depression.
Psychedelics used to combat anxiety and depression, not to get high
An international study led by UBC Okanagan researchers suggests repeated use of small doses of psychedelics such as psilocybin or LSD can be a valuable tool for those struggling with anxiety and depression.
The study, recently published in Nature: Scientific Reports, demonstrated fewer symptoms of anxiety and depression, and greater feelings of wellbeing among individuals who reported consuming psychedelics in small quantities, or microdosing, compared to those who did not.
Microdosing involves regular self-administration of psychedelic substances in amounts small enough to not impair normal cognitive functioning.
Considering this is the largest psychedelic microdosing study published to date, the results are encouraging, says UBCO doctoral student and lead author Joseph Rootman.
“In total, we followed more than 8,500 people from 75 countries using an anonymous self-reporting system—about half were following a microdosing regimen and half were not,” Rootman explains. “In comparing microdosers and non-microdosers, there was a clear association between microdosing and fewer symptoms of depression, anxiety and stress—which is important given the high prevalence of these conditions and the substantial suffering they cause.”
The study is also the first to systematically examine the practice of stacking, or combining microdoses of psychedelics with other substances like niacin, lions mane mushrooms and cacao, which some believe work in conjunction to maximize benefit.
Rootman works with Dr. Zach Walsh, a psychology professor in UBCO’s Irving K. Barber Faculty of Arts and Social Sciences. Dr. Walsh says it’s an exciting time for research in this area.
“These findings highlight adults who are microdosing to treat their mental health conditions and enhance their wellbeing—rather than simply to get high,” says Dr. Walsh. “We have an epidemic of mental health problems, with existing treatments that don’t work for everyone. We need to follow the lead of patients who are taking these initiatives to improve their wellbeing and reduce suffering.”
Study co-author Kalin Harvey is the chief technology officer of Quantified Citizen, a mobile health research platform. He says this study highlights the potential of citizen science.
“The use of citizen science allows us to examine the effects of behaviours that are difficult to study in the lab due to regulatory challenges and stigma associated with the now discredited ‘war on drugs.’”
According to the Canadian Mental Health Association, one in five Canadians personally experience a mental health problem or illness each year. This is one of the many reasons Dr. Walsh says conducting innovative psychological research is imperative.
“These cross-sectional findings are promising and highlight the need for further investigation to better determine the impacts of factors like dosage and stacking,” explains Dr. Walsh.
“While the data is growing to support the use of psychedelics like psilocybin in large doses to treat depression and addiction—our data also helps to expand our understanding of how psychedelics may also help in smaller doses.”
Original Article: UBCO study finds psychedelic microdosing improves mental health
More from: University of British Columbia
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Small doses of psychedelics
- DMT for Depression? Clinical Trial Finds Hallucinogen Significantly Reduces Symptoms
U.K.-based Small Pharma is conducting a study of DMT and its potential for treating major depressive disorder.
- This hallucinogen is looking pretty promising for depression treatment
In addition to supportive psychotherapy, participants — all of whom were diagnosed with moderate to severe depression — were given a one-time dose of 21.5mg, which resulted in a 20- to 30-minute ...
- Psychedelic Succeeds as Quick Depression Fix in Early Trial
Paired with supportive therapy, a 21.5-mg infusion of the agent, dubbed SPL026, significantly reduced depressive symptoms by 7.4 points more than placebo (P=0.02) at 2 weeks after treatment when using ...
- Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings
This stage allowed Small Pharma to assess the durability of the antidepressant effect as well as the comparative efficacy and safety of a one vs. two-dose regimen of its psychedelic compound. Topline ...
- Too good to be brew! DMT - the potent psychedelic in Ayahuasca - treats depression after a SINGLE dose, cutting-edge clinical trial shows
DMT — the most potent psychedelic known to man — treats people with severe depression after a single dose, a cutting-edge ... was carried out in 2021 by Small Pharma, a biotech company ...
Go deeper with Google Headlines on:
Small doses of psychedelics
[google_news title=”” keyword=”small doses of psychedelics” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Microdoses of psychedelics
- Psychedelic Sunday: Ketamine Assisted Therapy
When will capital markets catch up to psychedelic industry? Ronan Levy, CEO and Co-Founder of Field Trip, discusses strategy behind focusing on ketamine assisted therapy. Adult-use psychedelic ...
- Top 3 Psychedelic Storylines To Watch In 2023
2022 was a milestone year for the psychedelic industry and its advocates, with massive victories in the realms of decriminalization and legalization, clinical trials, and business. And it seems ...
- What Psychedelics Can Teach Us About Human Connection
In the field of psychology, there is a new, tsunami-like wave of interest in the use of psychedelic drugs as a compliment to traditional therapy, with new studies published weekly and research centers ...
- Mass. lawmakers propose decriminalizing ‘magic mushrooms,’ other psychedelics
Research has shown that psychedelics can be used to positively impact myriad conditions, opioid use disorder and depression among them. Meanwhile, a 2016 study published in The Lancet Psychiatry ...
- A Psychologist Demystifies The Trend Of Microdosing Psychedelics
Take, for example, this study published in the academic journal Nature. It explores the use of microdoses of psychedelic substances, specifically psilocybin, and their effects on mental health and ...
Go deeper with Google Headlines on:
Microdoses of psychedelics
[google_news title=”” keyword=”microdoses of psychedelics” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]